California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Johnson & Johnson is reportedly exploring the acquisition of biopharmaceutical company Intra-Cellular Therapies, according to Bloomberg News. The potential deal, valued at approximately $10 billion, could be finalized as early as this week, though discussions remain in early stages.
Intra-Cellular Therapies is renowned for Caplyta, its FDA-approved treatment for schizophrenia and bipolar disorders. Acquiring the company would bolster J&J’s neuroscience portfolio, helping mitigate revenue declines expected from upcoming patent expirations on its blockbuster drugs.
Despite the promising prospects, sources caution that negotiations may not result in a finalized agreement. Intra-Cellular’s stock surged nearly 15% last Friday, reflecting heightened investor optimism over the potential acquisition.
J&J continues to focus on high-growth therapeutic areas to strengthen its pharmaceutical division amidst growing market competition. If successful, this acquisition would align with the company's strategy to expand its innovative treatments and sustain long-term growth.
